pancreatic cancer

by Medical University of South Carolina edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source A new study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, sheds light on why pancreatic tumors with the KRAS G12R mutation behave differently from other KRAS-driven cancers and why […]

by Tokyo University of Science edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source TUS researchers uncovered a strong link between reduced CTDNEP1 expression and pancreatic cancer progression. They found that low levels are associated with early-stage tumors, abnormalities in major cancer-related genes, and lower survival rates, suggesting that CTDNEP1 may

by Molly Chiu, Baylor College of Medicine edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Individual clinical and immune correlative data. a–c, Radiographic response (a) and immune activity against both nontargeted (b) and targeted (c) TAAs pre-infusion and post-infusion in arm A patient no. 9 who achieved a CR after

by Nick Wurm,, Cold Spring Harbor Laboratory edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes CSHL’s Krainer lab has discovered a key oncogenic circuit driving aggressive pancreatic ductal adenocarcinoma (PDAC) progression. Using human PDAC tumor organoids, seen here, the team developed a potential RNA splicing-based therapeutic that collapses the circuit. Credit: Krainer lab/CSHL Pancreatic ductal adenocarcinoma

Emil Lou, MD, PhD DISCLOSURES January 07, 2026 Hi. I’m Dr Emil Lou, medical oncologist and specialist in gastrointestinal cancers at the University of Minnesota. It’s my pleasure to be here today to talk about all things, updates, and advances in pancreas adenocarcinoma. There are about 45,000 new cases of pancreatic cancer in the US each year, about

by Kayla Yup edited by Sadie Harley, reviewed by Andrew Zinin  Editors’ notes Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to stage 4 less than a year after

An IIT team in Genoa (Italy) has used artificial intelligence to identify an aptamer that enhances existing anticancer therapies Peer-Reviewed Publication Istituto Italiano di Tecnologia – IIT image: The small ring-like structures visible in the magnified area represent the RAD51 protein, which has adopted a non-functional shape as a result of its interaction with Apt1.

by Okayama University edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes Collagen plays dual roles in pancreatic cancer: as a physical fiber that obstructs macromolecular drug delivery, and as a bioactive signaling molecule that activates discoidin domain receptor 1 (DDR1) and drives a vicious fibrotic cycle. By blocking DDR1 signaling, researchers from Okayama and Tohoku Universities

by Linda Wang, University of California, Los Angeles edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Microscopy image showing a stem cell-engineered CAR-NKT cell (blue) attacking a human solid tumor cell (magenta). Credit: Lili Yang Lab/UCLA Pancreatic cancer is among the deadliest forms of cancer, with most patients diagnosed after the disease has already spread throughout the

by Paul Hellmich, Technical University Munich edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Immunofluorescence image of pancreatic cancer cells that invade nerves: nerve cells appear in green, tumor cells in red. Credit: Ekin Demir / TUM Pancreatic cancer is one of the deadliest types of tumors. A team at the Technical University of Munich (TUM) reports that